Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:SNSS

Sunesis Pharmaceuticals (SNSS) Stock Price, News & Analysis

Sunesis Pharmaceuticals logo

About Sunesis Pharmaceuticals Stock (NASDAQ:SNSS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$2.38
$5.32
52-Week Range
N/A
Volume
1.20 million shs
Average Volume
4.33 million shs
Market Capitalization
$96.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Receive SNSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sunesis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNSS Stock News Headlines

Peter J Barris's Net Worth
AQSZF Aequus Pharmaceuticals Inc.
These guys expect TSLA to reach $700 a share by August
Twitter lit up this morning after someone put a $4,000,000 bet on TSLA. These guys lit up the $700 strike calls for August 2025… This is odd, considering Tesla only trades for around $350 a share today… In other words, these guys are betting that Tesla’s stock will surge by 100% over the months ahead. In my opinion, that’s an incredibly risky bet. A lot can happen between now and then… Besides, there is a better way to target that same 100% return without waiting until August.
4 Breakout Stocks to Watch Going Into Labor Day
4 Stocks Under $10 to Trade Now
See More Headlines

SNSS Stock Analysis - Frequently Asked Questions

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) posted its quarterly earnings data on Sunday, November, 15th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.01.

Sunesis Pharmaceuticals shares reverse split before market open on Thursday, September 3rd 2020. The 1-10 reverse split was announced on Wednesday, September 2nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sunesis Pharmaceuticals investors own include SELLAS Life Sciences Group (SLS), Novavax (NVAX), NVIDIA (NVDA), QUALCOMM (QCOM), OPKO Health (OPK), TherapeuticsMD (TXMD) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
11/15/2020
Today
1/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SNSS
CUSIP
86732860
Fax
N/A
Employees
24
Year Founded
N/A

Profitability

Net Income
$-23,330,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.07 million
Book Value
$1.42 per share

Miscellaneous

Free Float
N/A
Market Cap
$96.26 million
Optionable
Optionable
Beta
2.27
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:SNSS) was last updated on 1/31/2025 by MarketBeat.com Staff
From Our Partners